Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RELUGOLIX vs REPOTRECTINIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RELUGOLIX vs REPOTRECTINIB: Safety Overview

Metric RELUGOLIX REPOTRECTINIB
Total FAERS Reports 20,660 187
Deaths Reported 958 27
Death Rate 4.6% 14.4%
Hospitalizations 1,699 48
Average Patient Age 72.4 yrs 60.8 yrs
% Female Patients 1.4% 61.1%
FDA Approval Date Dec 18, 2020 Jun 11, 2024
Manufacturer Sumitomo Pharma America, Inc. E.R. Squibb & Sons, L.L.C.
Route ORAL ORAL
Marketing Status Prescription Prescription